Traditional Chinese medicine, Fuzheng Kang‑Ai decoction, inhibits metastasis of lung cancer cells through the STAT3/MMP9 pathway Corrigendum in /10.3892/mmr.2021.12244

Li,Longmei; Wang,Sumei; Yang,Xiaobin; Long,Shunqin; Xiao,Shujing; Wu,Wanyin; Hann,Swei Sunny

doi:10.3892/mmr.2017.6905

Traditional Chinese medicine, Fuzheng Kang‑Ai decoction, inhibits metastasis of lung cancer cells through the STAT3/MMP9 pathway

Corrigendum in: /10.3892/mmr.2021.12244

Authors:
- Longmei Li
- Sumei Wang
- Xiaobin Yang
- Shunqin Long
- Shujing Xiao
- Wanyin Wu
- Swei Sunny Hann
View Affiliations

Affiliations: Laboratory of Tumor Biology and Targeted Therapies of TCM, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, Guangdong 510120, P.R. China, Department of Medical Oncology, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, Guangdong 510120, P.R. China, Laboratory of Tumor Biology and Targeted Therapies of TCM, Guangdong Provincial Hospital of Chinese Medicine, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, Guangdong 510120, P.R. China
Published online on: June 30, 2017 https://doi.org/10.3892/mmr.2017.6905
Pages: 2461-2468
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lung cancer is a leading cause of cancer‑associated mortality worldwide, including in developing countries such as China. Traditional Chinese medicine may provide a novel insight for the treatment of patients with lung cancer. The present study aimed to uncover the mechanism by which the Chinese herbal medicine, Fuzheng Kang‑Ai (FZKA), functions on lung cancer cell metastasis. The results demonstrated that treatment with FZKA markedly inhibited cell viability, migration and invasion of lung cancer cells, as determined by cell viability and Transwell assays. Notably, the activity and expression of matrix metalloproteinase 9 (MMP9) was significantly inhibited by FZKA treatment on lung cancer cells, as determined by an MMP9 activity assay and western blot analysis. Furthermore, FZKA markedly inhibited epithelial‑mesenchymal transition (EMT) of lung cancer cells by inhibiting the expression of the mesenchymal markers N‑cadherin and vimentin. In addition, activation of the oncoprotein signal transducer and activator of transcription 3 (STAT3) was suppressed following treatment with FZKA. Conversely, overexpression of STAT3 was able to rescue MMP9 activity following FZKA treatment. The present study indicated that FZKA may inhibit lung cancer metastasis via the STAT3/MMP9 pathway and EMT, suggesting that FZKA may serve as a novel promising therapeutic strategy for the treatment of patients with late stage lung cancer.

View Figures

View References

1	Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
2	Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
3	Chen W, Zheng R, Zhang S, Zhao P, Li G, Wu L and He J: Report of incidence and mortality in China cancer registries, 2009. Chin J Cancer Res. 25:10–21. 2013.PubMed/NCBI
4	Verdecchia A, Francisci S, Brenner H, Gatta G, Micheli A, Mangone L, Kunkler I, et al: EUROCARE-4 Working Group: Recent cancer survival in Europe: A 2000–02 period analysis of EUROCARE-4 data. Lancet Oncol. 8:784–796. 2007. View Article : Google Scholar : PubMed/NCBI
5	Thomas G: Furin at the cutting edge: From protein traffic to embryogenesis and disease. Nat Rev Mol Cell Biol. 3:753–766. 2002. View Article : Google Scholar : PubMed/NCBI
6	Fidler IJ: The pathogenesis of cancer metastasis: The ‘seed and soil’ hypothesis revisited. Nat Rev Cancer. 3:453–458. 2003. View Article : Google Scholar : PubMed/NCBI
7	Rhee JS and Coussens LM: RECKing MMP function: Implications for cancer development. Trends Cell Biol. 12:209–211. 2002. View Article : Google Scholar : PubMed/NCBI
8	Wang R, Ke ZF, Wang F, Zhang WH, Wang YF, Li SH and Wang LT: GOLPH3 overexpression is closely correlated with poor prognosis in human non-small cell lung cancer and mediates its metastasis through upregulating MMP-2 and MMP-9. Cell Physiol Biochem. 35:969–982. 2015. View Article : Google Scholar : PubMed/NCBI
9	Ahmad R, Shihab PK, Jasem S and Behbehani K: FSL-1 induces MMP-9 production through TLR-2 and NF-κB/AP-1 signaling pathways in monocytic THP-1 cells. Cell Physiol Biochem. 34:929–942. 2014. View Article : Google Scholar : PubMed/NCBI
10	Yang CQ, Li W, Li SQ, Li J, Li YW, Kong SX, Liu RM, Wang SM and Lv WM: MCP-1 stimulates MMP-9 expression via ERK 1/2 and p38 MAPK signaling pathways in human aortic smooth muscle cells. Cell Physiol Biochem. 34:266–276. 2014. View Article : Google Scholar : PubMed/NCBI
11	Cheng X, Yang Y, Fan Z, Yu L, Bai H, Zhou B, Wu X, Xu H, Fang M, Shen A, et al: MKL1 potentiates lung cancer cell migration and invasion by epigenetically activating MMP9 transcription. Oncogene. 34:5570–5581. 2015. View Article : Google Scholar : PubMed/NCBI
12	Sreekumar R, Sayan BS, Mirnezami AH and Sayan AE: MicroRNA control of invasion and metastasis pathways. Front Genet. 2:582011. View Article : Google Scholar : PubMed/NCBI
13	Xia H and Hui KM: MicroRNAs involved in regulating epithelial-mesenchymal transition and cancer stem cells as molecular targets for cancer therapeutics. Cancer Gene Ther. 19:723–730. 2012. View Article : Google Scholar : PubMed/NCBI
14	Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C and Darnell JE Jr: Stat3 as an oncogene. Cell. 98:295–303. 1999. View Article : Google Scholar : PubMed/NCBI
15	Song L, Turkson J, Karras JG, Jove R and Haura EB: Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells. Oncogene. 22:4150–4165. 2003. View Article : Google Scholar : PubMed/NCBI
16	Liu F, Zhang T, Zou S, Jiang B and Hua D: B7-H3 promotes cell migration and invasion through the Jak2/Stat3/MMP9 signaling pathway in colorectal cancer. Mol Med Rep. 12:5455–5460. 2015.PubMed/NCBI
17	Yang XB, Wu WY, Long SQ, Deng H, Pan ZQ, He WF, Zhou YS, Liao GY, Li QP, Xiao SJ and Cai JZ: Fuzheng Kang'ai decoction combined with gefitinib in advanced non-small cell lung cancer patients with epidermal growth factor receptor mutations: Study protocol for a randomized controlled trial. Trials. 16:1462015. View Article : Google Scholar : PubMed/NCBI
18	Wu WY, Yang XB, Deng H, Long SQ, Sun LS, He WF, Zhou YS, Liao GY, Chan SM and Shan SP: Treatment of advanced non-small cell lung cancer with extracorporeal high frequency thermotherapy combined with Chinese medicine. Chin J Integr Med. 16:406–410. 2010. View Article : Google Scholar : PubMed/NCBI
19	Yang XB, Wu WY, Long SQ, Deng H and Pan ZQ: Effect of gefitinib plus Chinese herbal medicine (CHM) in patients with advanced non-small-cell lung cancer: A retrospective case-control study. Complement Ther Med. 22:1010–1018. 2014. View Article : Google Scholar : PubMed/NCBI
20	Zheng F, Wu J, Li X, Tang Q, Yang L, Yang X, Wu W and Hann SS: Chinese Herbal Medicine Fuzheng Kang-Ai Decoction inhibited lung cancer cell growth through AMPKα-mediated induction and interplay of IGFBP1 and FOXO3a. Evid Based Complement Alternat Med. 2016:50607572016. View Article : Google Scholar : PubMed/NCBI
21	Iwatsuki M, Mimori K, Yokobori T, Ishi H, Beppu T, Nakamori S, Baba H and Mori M: Epithelial-mesenchymal transition in cancer development and its clinical significance. Cancer Sci. 101:293–299. 2010. View Article : Google Scholar : PubMed/NCBI
22	Wan L, Pantel K and Kang Y: Tumor metastasis: Moving new biological insights into the clinic. Nat Med. 19:1450–1464. 2013. View Article : Google Scholar : PubMed/NCBI
23	Lee JM, Dedhar S, Kalluri R and Thompson EW: The epithelial-mesenchymal transition: New insights in signaling, development and disease. J Cell Biol. 172:973–981. 2006. View Article : Google Scholar : PubMed/NCBI
24	Lui VW, Wong EY, Ho Y, Hong B, Wong SC, Tao Q, Choi GC, Au TC, Ho K, Yau DM, et al: STAT3 activation contributes directly to Epstein-Barr virus-mediated invasiveness of nasopharyngeal cancer cells in vitro. Int J Cancer. 125:1884–1893. 2009. View Article : Google Scholar : PubMed/NCBI
25	Guo K, Ma Q, Li J, Wang Z, Shan T, Li W, Xu Q and Xie K: Interaction of the sympathetic nerve with pancreatic cancer cells promotes perineural invasion through the activation of STAT3 signaling. Mol Cancer Ther. 12:264–273. 2013. View Article : Google Scholar : PubMed/NCBI
26	El-Badrawy MK, Yousef AM, Shaalan D and Elsamanoudy AZ: Matrix metalloproteinase-9 expression in lung cancer patients and its relation to serum mmp-9 activity, pathologic type, and prognosis. J Bronchology Interv Pulmonol. 21:327–334. 2014. View Article : Google Scholar : PubMed/NCBI
27	Vilen ST, Salo T, Sorsa T and Nyberg P: Fluctuating roles of matrix metalloproteinase-9 in oral squamous cell carcinoma. ScientificWorldJournal. 2013:9205952013. View Article : Google Scholar : PubMed/NCBI
28	Backstrom JR and Tökés ZA: The 84-kDa form of human matrix metalloproteinase-9 degrades substance P and gelatin. J Neurochem. 64:1312–1318. 1995. View Article : Google Scholar : PubMed/NCBI
29	Yu H and Jove R: The STATs of cancer-new molecular targets come of age. Nat Rev Cancer. 4:97–105. 2004. View Article : Google Scholar : PubMed/NCBI
30	Ao N and Liu Y, Bian X, Feng H and Liu Y: Ubiquitin-specific peptidase 22 inhibits colon cancer cell invasion by suppressing the signal transducer and activator of transcription 3/matrix metalloproteinase 9 pathway. Mol Med Rep. 12:2107–2113. 2015.PubMed/NCBI
31	Shirakihara T, Saitoh M and Miyazono K: Differential regulation of epithelial and mesenchymal markers by deltaEF1 proteins in epithelial mesenchymal transition induced by TGF-beta. Mol Biol Cell. 18:3533–3544. 2007. View Article : Google Scholar : PubMed/NCBI
32	Gupta GP and Massagué J: Cancer metastasis: Building a framework. Cell. 127:679–695. 2006. View Article : Google Scholar : PubMed/NCBI
33	Orlichenko LS and Radisky DC: Matrix metalloproteinases stimulate epithelial-mesenchymal transition during tumor development. Clin Exp Metastasis. 25:593–600. 2008. View Article : Google Scholar : PubMed/NCBI